Bcl-6 mutation status provides clinically valuable information in early-stage B-cell chronic lymphocytic leukemia.

摘要: In B-cell chronic lymphocytic leukemia (B-CLL), somatic mutation of IgVH genes defines a subgroup with favorable prognosis, whereas the absence mutations is correlated worse outcome. Mutations BCL-6 gene are also observed in subset B-CLL, but clinical significance this molecular alteration remains uncertain. We examined distribution and 95 well-characterized patients Binet stage A them clinical, laboratory, cytogenetic findings disease progression. were only cases harboring mutated IgVH. Unexpectedly, coexistence was shorter treatment-free interval (TFI) compared to (median, 55 months vs not reached; P=0.01), resembling course unmutated (median TFI, 44 months). As expected, deletions 17p13 (P53 locus) 11q22 (ATM IgVH, except one patient who showed both BCL-6. No other statistically significant differences among genetic subgroups. Our data indicate that identify B-CLL high risk progression despite presence gene.